Table 3. The association between ETE and clinicopathological characteristics or gene mutations in PTC.
| Characteristics | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| OR (95% CI) for ETE | P value | OR (95% CI) for ETE | P value | ||
| Sex (female vs. male) | 0.595 (0.182–1.943) | 0.390 | NA | NA | |
| Age (≥55 vs. <55 years) | 0.380 (0.040–3.601) | 0.399 | NA | NA | |
| Tumor size (>1 vs. ≤1 cm) | 5.833 (1.904–17.808) | 0.002 | 8.831 (1.971–35.578) | 0.004 | |
| HT (yes vs. no) | 0.116 (0.035–0.389) | <0.001 | 0.112 (0.025–0.499) | 0.004 | |
| Multifocality (yes vs. no) | 1.429 (0.388–5.258) | 0.592 | NA | NA | |
| LNMN (≥5 vs. <5) | 0.888 (0.331–2.382) | 0.813 | NA | NA | |
| RET mutation (yes vs. no) | 0.423 (0.870–2.065) | 0.288 | NA | NA | |
| BRAF mutations only* | 4.313 (1.097–16.955) | 0.036 | 10.567 (1.748–63.873) | 0.010 | |
| Two gene mutations* | 8.250 (1.453–46.859) | 0.017 | 8.654 (1.453–68.603) | 0.041 | |
| Three gene mutations* | 4.500 (0.570–35.519) | 0.154 | 10.925 (0.740–161.185) | 0.082 | |
*Comparisons were performed between BRAF mutation groups (BRAF mutations only, BRAF + one gene mutations and BRAF + two gene mutations) and non-BRAF mutation group. ETE, extrathyroidal extension; PTC, papillary thyroid carcinoma; OR, odds ratio; CI, confidence interval; HT, Hashimoto’s thyroiditis; LNMN, the Metastatic number of lymph nodes.